OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Organon & Co.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$13.75−0.01 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $3.72B
- P/E (TTM)
- 17.6
- Dividend yield
- 2.47%
Organon & Co. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 52.7%
- Operating margin
- –
- Net margin
- 3.4%
- Return on equity, FY2025
- 30.6%
Financial strength
- Current ratio
- 1.95
- Debt to equity
- 8.50
- Debt to assets
- 64.9%
- Cash to current liabilities
- 43.3%
Valuation
- P/E ratio
- 17.6
- Price to sales
- 0.61
- Price to book
- 3.70
- Dividend yield
- 2.47%